CASI Pharmaceuticals, Inc. (NASDAQ: CASI) has disclosed today that its partner Juventas has started the Phase II registration study for CNCT19 in China in patients. The company has also commenced hiring the first patient. This is the greatest accomplishment of the biotechnology firm. Juventas